PTC Therapeutics, Inc. (PTCT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong initial revenues from Sephience, significant cash reserves, and positive feedback from patients and physicians, indicating growth potential. The Q&A reinforces confidence in Sephience's uptake and patient adherence, despite some lack of specific guidance. The market cap suggests a moderate reaction, but overall, the sentiment leans positive due to new product launches and strategic market expansions.
Key Financial Performance
Total Revenue $211 million for the third quarter of 2025, which includes the first revenue from the Sephience launch and contributions from the DMD franchise.
Sephience Revenue $19.6 million as of September 30, 2025, with $14.4 million from the U.S. and $5.2 million ex U.S. This is the first revenue from the Sephience launch.
DMD Franchise Revenue $86 million for the quarter, with Translarna net product revenue of $51 million and Emflaza net product revenue of $35 million.
Evrysdi Royalty Revenue $71 million for the third quarter of 2025, based on Roche's global revenue of approximately $532 million.
Non-GAAP R&D Expense $91 million for the third quarter of 2025, excluding $9 million in noncash stock-based compensation expense. This is a decrease from $152 million in the third quarter of 2024, excluding $9 million in noncash stock-based compensation expense. The decrease reflects reduced spending on certain programs.
Non-GAAP SG&A Expense $74 million for the third quarter of 2025, excluding $10 million in noncash stock-based compensation expense. This is an increase from $63 million in the third quarter of 2024, excluding $10 million in noncash stock-based compensation expense, due to increased commercial activities.
Cash, Cash Equivalents, and Marketable Securities $1.68 billion as of September 30, 2025, compared to $1.14 billion as of December 31, 2024. The increase reflects the purchase of 90% of Sephience annual global net sales payment obligation for $225 million upfront and future sales-based milestone payments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Sephience launch: Initiated global launch in Europe and the U.S., generating $19.6 million in revenue as of September 30, 2025. U.S. revenue was $14.4 million, and ex-U.S. revenue was $5.2 million. Received 521 patient start forms from U.S. centers, covering all ages, disease severities, and treatment histories. Demonstrated 70% greater reduction in phenylalanine levels compared to BH4 in a head-to-head study.
DMD franchise: Generated $86 million in revenue, with $51 million from Translarna and $35 million from Emflaza.
Evrysdi royalties: Roche's global revenue of $532 million resulted in $71 million in royalty revenue for PTC.
Geographic expansion: Sephience launched in the U.S. and Europe, with preparations for Japan launch in Q4 and recent approval in Canada. Anticipating regulatory approvals in Japan and Brazil later this year.
Financial position: Ended Q3 with $1.68 billion in cash, enabling cash flow breakeven and strategic business development activities.
Cost management: Non-GAAP R&D expense was $91 million, down from $152 million in Q3 2024. Non-GAAP SG&A expense was $74 million, up from $63 million in Q3 2024.
Sephience pricing strategy: Maintaining a narrow pricing corridor during the early launch stage.
Business development: Acquired 90% of Sephience annual global net sales payment obligation for $225 million upfront, expecting significant value creation.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals and Compliance: The company is awaiting regulatory approvals in Japan and Brazil for Sephience, which could delay market entry and revenue generation in these regions. Additionally, the need to secure pricing and reimbursement across international markets poses a challenge.
Market Access and Payer Policies: Although initial payer engagement in the U.S. has been positive, the company anticipates a stabilization of the payer mix, which could impact revenue projections. Medicaid and Medicare plans are still finalizing their policies, creating uncertainty in the payer landscape.
Supply Chain and Launch Execution: The simultaneous launch of Sephience in multiple regions, including the U.S., Europe, and upcoming markets like Japan, requires robust supply chain management and operational execution. Any disruptions could impact product availability and revenue.
Competitive Pressures: The company faces competition in the PKU treatment market, which could impact Sephience's market share and revenue growth. Additionally, maintaining brand loyalty for existing products like Translarna and Emflaza amidst generic entries is a challenge.
Economic and Financial Risks: The company has made significant financial commitments, including a $225 million upfront payment for Sephience-related obligations. While the company is well-capitalized, these financial outlays could strain resources if revenue targets are not met.
Strategic Execution Risks: The company is heavily reliant on the success of Sephience for its near-term path to profitability. Any setbacks in its adoption, efficacy perception, or market penetration could adversely affect financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has narrowed its 2025 full-year revenue guidance to $750 million to $800 million, which is at the upper end of the initial revenue guidance range.
Sephience Launch and Revenue Expectations: The Sephience global launch is expected to be a foundational product for sustainable growth and near-term profitability. Sephience generated $19.6 million in revenue as of September 30, 2025, and the company anticipates continued momentum in the U.S., Europe, and upcoming launches in Japan, Canada, and Brazil.
Regulatory Approvals and Market Expansion: Regulatory approval for Sephience in Japan and Brazil is anticipated later this year, with Canada already approved. The company is preparing health technology assessment dossiers to secure pricing and reimbursement in international markets.
Huntington's Disease Program: A meeting with the FDA is planned for Q4 2025 to align on the study design for the next efficacy study and discuss the data package for a potential accelerated approval application.
Friedreich's Ataxia Program: A meeting with the FDA is planned this quarter to discuss potential next steps for the program.
Translarna NDA: The NDA for Translarna remains under FDA review.
Financial Position and Strategic Plans: The company ended Q3 2025 with $1.68 billion in cash, enabling it to reach cash flow breakeven and participate in strategic business development activities. An R&D Day is scheduled for December 2, 2025, to share progress on research programs.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives confidence that Sephience will maintain durability and that patients will stay on therapy?
A:The CEO highlighted the highly differentiated profile of Sephience, its uptake across all patient segments, and positive feedback from physicians and patients. Early results show patients responding well, including severe cases, with benefits like diet liberalization and Phe reduction. Clinical studies showed up to a 75% response rate, which supports the potential for broad patient benefit.
Q:What magnitude of Phe reduction are doctors and payers looking for to keep patients on treatment beyond the trial period?
A:Doctors and payers have varying expectations: some consider 15-20% Phe reduction meaningful for severe cases, while others look for 30% reduction or improvements in patients' overall well-being, cognitive function, and mood. Clinical trial data showed 66-75% response rates with good adherence.
Q:What is the timeline from a new start form to a patient receiving Sephience?
A:The timeline varies by plan. For commercial plans, it can take days to 2-4 weeks. Government plans like Medicare and Medicaid may take longer. The PTC Cares team facilitates the process, and there have been no major obstacles or restrictions for access.
Q:What is the current rate of start forms and momentum for Sephience?
A:The company has seen consistent rates of start forms and patients getting on the drug since launch. About 2/3 of the centers of excellence have prescribed more than one prescription, indicating good momentum.
Q:What is the patient profile for new prescribers of Sephience?
A:Patients range from infants to 79 years old, with contributions from all segments, including treatment-naive patients and those switching from other therapies like Palynziq. The average patient weight is around 45 kilograms.
Q:What are the updates on Sephience's launch in Europe and Japan?
A:In Europe, the company is in the free pricing period in Germany and has submitted HTA dossiers in Southern Europe. In Japan, approval is expected by year-end, with pricing negotiations to follow. The launch in Japan is anticipated in the first quarter of 2026.
Q:What is the opportunity for Sephience in Brazil?
A:Brazil has over 6,000 PKU patients, and the company expects approval this quarter. Pricing will be referenced to other markets, and the launch is expected to generate revenue in 2026. The patient population in Brazil may include older adolescents due to differences in newborn screening practices.
Q:How is the response rate for Sephience tracking in the real world?
A:It is too early to provide specific numbers, but early feedback indicates good response rates and momentum with refills. Most patients prescribed Sephience early on have continued with refills.
Q:What is the company's approach to diet liberalization for Sephience patients?
A:The company emphasizes a gradual and managed approach to diet liberalization, working closely with dietitians and nutritionists to ensure patients maintain control of phenylalanine while enjoying dietary flexibility.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the percentage of patients expected to stay on treatment following the trial period, the exact response rate for Sephience in the real world, and revenue projections for the drug. They also did not provide detailed metrics on the breakout of patient segments or the exact impact of diet liberalization on patient weight.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APHENITY extension
Article brand
BH crossover
Brazil pricing
Canada approval
Cares team
Day Tuesday
EMEA approval
ESPKU roundtable
Emflaza program
Europe United
Germany
PKU community
Phe
Sephience PKU
Sephience launch
Sephience patient
Translarna
approval th
care provider
channel
form
head study
health care
market access
momentum
patient Sephience
phenylalanine
platform
policy
response
spectrum PKU
stage launch
start
switch treatment
th Sephience
today result
uncertainty result
PTCT Transcript
PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
PTC Therapeutics, Inc. (PTCT) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call shows strong financial performance with a 15% YoY revenue increase and significant net income improvement. Positive cash flow and strategic R&D investments are promising. Despite some risks in forward-looking statements, the financials and optimistic guidance outweigh uncertainties. Given the company's market cap, this is likely to lead to a positive stock price movement.
PTC Therapeutics, Inc. (PTCT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
PTCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
